IPO

Aardvark Therapeutics, a San Diego-based biotech company, is on track for an initial public offering (IPO) this summer. The company is developing a weight loss pill, ARD-101, that has shown promise in early-stage trials. ARD-101 works differently from other weight loss drugs by targeting two gut hormones, GLP-1 and CCK, which could potentially reduce side … Read more

CG Oncology is a biotech company focused on developing innovative treatments for bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Their two main clinical programs involve cretostimogene grenadenorepvec (CG0070), an oncolytic immunotherapy. CG Oncology filed confidentially on October 27, 2023. The company filed publicly this week with the SEC to raise up to $100 million … Read more

Synthetic.com’s publisher and editor, Simons Chase, interviews Matthew McKnight. Matt is the Chief Commercial Officer of Ginkgo Bioworks where he also leads the company’s biosecurity platform, Concentric by Ginkgo. Prior to Ginkgo, Matt spent 7 years as an investor at IndUS Growth Partners and was the President and COO of Decision Resources Group. He has … Read more

Immuneering Corp. applies translational bioinformatics to drug development. Its biopharmaceutical therapeutic focus is oncologic and neurologic diseases. The company has more than a decade of experience in translational bioinformatics that it believes allow it to generate superior insights into drug mechanisms of action and patient treatment responses. Immuneering has developed a disease-agnostic platform for human … Read more

Absci Corp describes itself as an AI-powered integrated drug creation platform. The company creates protein-based drugs (biologics) by unifying biologic drug discovery and cell line development into one process. This places Absci squarely under the umbrella of synthetic biology. The challenge in next-generation biologics is the linear steps needed to screen and select desired molecular … Read more

Caribou Biosciences is a clinical-stage biopharmaceutical company innovating in next-generation, genome-edited cell therapies. Its CRISPR hybrid RNA-DNA (chRDNA) guide technology has demonstrated superior specificity and high efficiency in preclinical studies, and, according to the company, has the potential to generate gene and cell therapies in oncology and in therapeutic areas beyond oncology, including immune cell … Read more

Zymergen, an Emeryville, California–based synthetic biotechnology firm, recently raised $500 million in an initial public offering (IPO) of stock on the NASDAQ exchange that values the 8-year-old company at over $3 billion. Four months ago, Zymergen launched its first product, Hyaline, a polymer film for electronic displays that it developed with Sumitomo Chemical. Zymergen makes … Read more

Ginkgo Bioworks, Inc.’s (“Ginkgo”) founders have been working together for nearly twenty years since they first met at MIT. They launched Ginkgo in 2008 with the consistent goal of developing a platform that makes cell programming easier for their customers and partners. Ginkgo’s platform leverages advanced robotic automation, proprietary software, and data analytics to continuously … Read more